CAR:

Yizhao Chen1, Qianling Xin2, Mengjuan Zhu3

  • 1Department of Pharmacy, The Third Affiliated Hospital of Anhui Medical University, Hefei First People's Hospital, Hefei, China; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.

PubMed
概括

化学抗原受体巨细胞 (CAR-M) 显示出治疗非瘤疾病的前景. 优化CAR细胞内域是提高CAR-M疗法的有效性和临床转换的关键.